To overcome the toxicity of chemotherapy, increasing attention has been paid to local drug delivery systems (DDSs). pH-Sensitive hydrogels have emerged as promising DDS materials in the biomedical field due to their remarkable characteristics. However, the pH environment in tumor varies from person to person, which makes the applicability of systems based on pH challenging. In this study, we developed a contractible hydroxypropyl methyl cellulose (HPMC)/Fe 3 O 4 hydrogel with dual-response pH and magnetic properties aiming to overcome the limitations of pH-sensitive hydrogel drug delivery systems and further increase their efficiency in tumor therapy. The HPMC/Fe 3 O 4 hydrogel could act as a drug delivery system that combines pH-sensitive triggering and magnetic dual-response drug release for synergistic chemo-magnetic hyperthermia therapy. The drug delivery profile of the HPMC/Fe 3 O 4 / doxorubicin hydrochloride (DOX) hydrogel was determined in vitro and revealed a remarkable pHsensitive performance. After synergistic chemo-magnetic hyperthermia treatment, mice with 4T1 breast cancer xenografts recovered without any recurrence or metastasis, demonstrating the synergistic effect of chemotherapy and magnetic hyperthermia therapy. Meanwhile, reduced toxicity and superior anticancer effects were achieved due to the combined effect of the pH and magnetic hyperthermia response properties. This study demonstrated the high efficacy and low toxicity of the improved design of HPMC/Fe 3 O 4 for drug delivery, which may provide a promising approach for the application of chemo-magnetic hyperthermia cancer therapy.
Introduction
Many efforts have been made over the past few decades to improve the available treatment options for cancer, but, to date, chemotherapy remains one of the most common approaches.
1,2
However, traditionally available anticancer drugs frequently cause severe systemic side effects due to a lack of ability to differentiate cancer cells from normal cells. The toxicity of chemotherapy drugs and the compliance of patients limit the dose that can be delivered, leading to a reduction in the therapeutic efficacy. [3] [4] [5] To overcome these drawbacks, increasing attention has been paid to local drug delivery systems (DDSs). Hydrogels, which are hydrophilic polymers swollen by water, 6 have emerged as promising DDS materials in the biomedical eld 7 due to their remarkable characteristics, such as their high biocompatibility, fabrication versatility, and similarity to the native extracellular matrix. In recent years, hydrogels employing newly developed polymers that respond to pH, temperature, light and electric elds, inducing on-demand or environmentally specic release kinetics, have achieved signicant progress as drug delivery systems. 8 Among these characteristics, the ability to respond to pH has attracted increasing attention. It is well known that one of the internal biological features of solid tumor microenvironments is acidosis. 9 It has been demonstrated that the extracellular tumor pH values are between pH 5 and 7 because of the high rate of glycolysis in the bloodstream.
10,11
Moreover, endosomes and lysosomes inside tumor cells exhibit much lower pH values, in the range of pH 4.5-5.5.
12,13
Thus, pH-sensitive hydrogels may be appropriate biomaterials for drug release in situ to achieve drug release only in the tumor and to minimize drug leakage to normal tissue. However, pH-sensitive hydrogels have some limitations. For example, release is triggered by the acidic tumor microenvironment and the pH may vary from person to person, which makes the applicability of systems based on pH challenging.
14 It is also well known that some hydrogels respond to temperature. 7, 15 Therefore, nding a pH and temperature dual-response hydrogel and changing the temperature to enhance the drug release might improve the results based on individual differences.
There are many strategies to change the local temperature of a tumor, such as hyperthermia ablation, a tumor therapy strategy that produces heat that contributes to tumor ablation. 16 Among hyperthermia ablation strategies, magnetic hyperthermia treatment is a technique by which magnetic nanoparticles absorb energy from a magnetic eld and convert the electromagnetic energy to heat, resulting in tumor ablation. 17, 18 Recently, an injectable and contractible hydroxypropyl methylcellulose (HPMC)/Fe 3 O 4 hydrogel has been developed for magnetic hyperthermia treatment of tumors in vivo, 19 which has many advantages. First, the high water content of the HPMC/Fe 3 O 4 hydrogel contributes to its biocompatibility, 20 Second, the HPMC/ Fe 3 O 4 hydrogel has a high thermal response, so its magnetic hydrothermal effects may enhance its drug delivery. 16, 21, 22 Third, in a previous study, we found that the HPMC/Fe 3 O 4 hydrogel is pH-sensitive, which is quite appropriate for the acidic tumor microenvironment, indicating it may be a good drug delivery system for the selective release of antineoplastic drugs, without hurting normal tissues. Finally, the HPMC/Fe 3 O 4 hydrogel is safe for medical use, since all the contents of this hydrogel have been used in clinical applications or in the biomedical eld.
23-29
However, the pure HPMC/Fe 3 O 4 hydrogel still has some limitations in tumor therapy. It has been reported that aer a heat shock, all cell types show increased thermoresistance and the required temperatures could not be achieved effectively under clinical conditions.
30
Additionally, the increasing temperature required by hyperthermia may be followed by aggravated pain, which may reduce the compliance of patients, limiting the therapeutic efficacy.
Based on consideration of the above limitations and studies that have shown that hyperthermia temperatures can provoke an increase in the tumor blood ow and make cells more sensitive to chemotherapy for increased drug delivery by higher perfusion, 31, 32 we thought that the HPMC/Fe 3 O 4 hydrogel might provide an ideal strategy for the synergistic chemotherapeutic and magnetic hyperthermia treatment of tumors.
In this study, we investigated the drug delivery prole of the HPMC/Fe 3 O 4 /doxorubicin hydrochloride (DOX) hydrogel in vitro and its therapeutic efficiency for synergistic magnetic hyperthermia treatment in vivo (Scheme 1 (JEOL Japan Electronics Co., Ltd, JEM-2100F) and the morphology of the HPMC/Fe 3 O 4 hydrogel was observed by SEM imaging. To prepare samples for TEM, appropriate amounts of particles were suspended in ethanol and loaded onto a copper grid for observation. The samples for SEM were dried at 37 C in an oven overnight while compressed with glass slides to make the surface smooth. spheres were placed in the center of the coil. An AMF was induced using a custom-built magnetic hyperthermia machine (frequency: 400 kHz; output power: 7.2 kw, coil diameter: 10 cm). An infrared thermal imaging instrument (Fortric Technology, Fortric225) was used to acquire the real-time temperature on the surface. All the images captured by infrared thermography were analyzed using the FOTRIC AnalyzIR soware. The longest and shortest diameters of the HPMC/Fe 3 O 4 in the AMF were measured using Vernier calipers to calculate the volume to estimate the change in volume of the hydrogel in the AMF at different times. The formula used to calculate the volume is
where D L is the longest diameter and D S is the shortest diameter of the tumor measured by a Vernier caliper.
In vitro drug release
To investigate the DOX release in vitro, 60 mL of HPMC/Fe 3 O 4 / DOX was place in a dialysis bag (8000-14000) with 940 mL phosphate buffered saline (PBS) at pH 5.5 or pH 7.4. Then, the whole dialysis bag was placed in a 50 mL centrifuge tube with 29 mL PBS added aerwards. The centrifuge tube was transferred to an incubated shaker to perform the release at 37 C and 120 rpm. At 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 24 h, 1 mL samples were taken from the tube and an additional 1 mL of pure PBS was added to maintain the medium volume. The tubes in the experimental group were exposed to AMF in the center of the coil for 1 min at 1 h, 4 h, 8 h, and 12 h. To investigate the efficiency of the DOX release, all the samples were measured using a UV-Vis spectrometer (Shimadzu UV-3600, Japan). The cumulative amount of DOX released from the HPMC/Fe 3 O 4 hydrogel with time was calculated. As a control, the DOX release without AMF exposure was performed using the same method. injected into a vein and blood samples were taken at different time points (7 and 14 days). To reect the liver and renal functions, some serum biochemical indicators were detected including total protein (TP), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin (ALB), blood urea nitrogen (BUN) and serum creatinine (sCr). The serum of the mice was analyzed using an automated biochemical analyzer (Rayto chemray 240, China).
In vitro and in vivo biosafety

Ablation efficiency in excised bovine liver
Different volumes (40, 60 and 80 mL) of HPMC/Fe 3 O 4 were injected into prepared excised bovine liver under ultrasound guiding and then exposed to AMF for different time periods (3, 5, 7 and 10 min). Additionally, the volumes of HPMC/Fe 3 O 4 were measured by ultrasound. Otherwise, elastography was used to detect rigidity changes in the HPMC/Fe 3 O 4 hydrogel aer AMF ablation. The ablation distance of the bovine liver was macroscopically measured from the border of the implant to the edge of the necrotic area.
The nude mouse 4T1 mouse breast cancer xenogra model
The 4T1 mouse breast cancer cell line was purchased from the Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China and cultured following the guidance with purchase. The cells were collected by digestion, centrifugation and dispersed in axenic PBS at the concentration of 1 Â 10 7 cell per 0.1 mL. 40 female SPF nude mice at a mean weight of 20 AE 0.3 g were injected with 0.1 mL of 4T1 cell suspension per mouse in the back near the right hind leg. All the animal experiments were approved by the Animal Welfare Ethics Committee of the Shanghai Sixth People's Hospital.
In vivo therapeutic efficiency
The HPMC/Fe 3 O 4 /DOX hydrogel was injected into anesthetized mice in the center of the tumor in situ under the guidance of real-time ultrasound. A far-infrared thermometer (Fortric Technology, Fortric225) was applied to monitor the peak surface temperature of the tumors continuously. Moreover, the tumor volumes and the weight of mice were macroscopically measured each day. The tumor volumes were estimated using the formula V ¼ D L D S 2 /2. Aer the magnetic hyperthermia treatment, all the mice were fed to observe their health status and the recurrence of the tumors and then euthanized. Two of each group were randomly chosen to be dissected to obtain the heart, liver, spleen, lung and kidney for hematoxylin and eosin staining (H&E staining) to observe the difference between the normal nude mice and the tumor-bearing mice. The survival ratio of the tumor-bearing mice was calculated using the formula R s ¼ N s /N t , where N s is the number of mice that survived and N t is the total number of mice. In addition, the tumor inhibition ratio of chemo-thermal therapy was calculated using the formula (Fig. S1c †) . The SEM image of the samples before and aer exposure to the alternating magnetic eld (AMF) demonstrated that the rough surface of the Fe 3 O 4 spheres was retained, so AMF did not change the structure of the Fe 3 O 4 spheres. Additionally, the Fe 3 O 4 spheres that were homogeneously dispersed before the AMF were gathered together aer the AMF process. This may be why the temperature increased more rapidly in the latter half of the heating process, since the heating efficiency is proportional to the thermal power per unit mass for magnetic materials.
39
To investigate the contents of the HPMC/Fe 3 O 4 hydrogel and any loss in the heating process, a thermogravimetric analysis was conducted. The thermogravimetric curves (Fig. 2a) 4 . Thus, the thermogravimetric curves indicate that the weight loss during the magnetic hyperthermia treatment is mainly due to the absorbed water. The swelling capacity ratio was determined to estimate the water absorption. Fig. 2b shows that the swelling capacity ratios of the HPMC/Fe 3 O 4 /DOX and HPMC/Fe 3 O 4 hydrogels are approximately (P > 0.05), which demonstrates there is no signicant difference between the two groups. The swelling capacity ratio of the HPMC/Fe 3 O 4 hydrogel in fetal bovine serum, which simulated the internal environment, showed an increase in the water content. As has been reported previously, a high water content provides physical similarity to tissues and can give hydrogels excellent biocompatibility and the capability to easily encapsulate hydrophilic drugs. 15, 40, 41 To determine whether HPMC/Fe 3 O 4 is injectable, its rheological properties were tested. The rheological property curve ( Fig. 2c and d) shows the shear-thinning character of the HPMC/Fe 3 O 4 hydrogel. Shear-thinning hydrogels ow like low-viscosity uids under shear stress during injection, but quickly recover their initial stiffness aer the removal of shear stress in the body.
42
During the injection process, the HPMC/Fe 3 O 4 hydrogel was injected into the body via the application of shear stress. The shear-thinning properties of the HPMC/Fe 3 O 4 hydrogel demonstrates that in the process of injection, as the stress strengthened, the HPMC/Fe 3 O 4 hydrogel gets thinner, which indicates that it can be injected into the body.
Heating efficiency of the HPMC/Fe 3 O 4 hydrogel
To select the optimal concentration of Fe 3 O 4 spheres in the HPMC/Fe 3 O 4 hydrogel, samples with different concentrations were place in a glass culture dish at the center of the coil with a thermography recording the temperature. As shown in Fig. 3a  and b S1a and b †) . Different volumes (40, 60, and 80 mL) of the HPMC/Fe 3 O 4 hydrogel were heated in the AMF. In Fig. S1d , † it can be seen that the temperature increase is positively correlated with the volume, while there was no signicant difference between the 60 mL and 80 mL volumes. Therefore, 60 mL was tentatively selected as the volume for ablation. Further experiments are required to select the injection volume.
In vitro drug release
To investigate the pH and magnetic dual-response of the HPMC/Fe 3 O 4 hydrogel, four sets of conditions were tested: in PBS at pH 7.4, in PBS at pH 5.5, in PBS at pH 5.5 with exposure to the AMF and in PBS at pH 7.4 with exposure to the AMF. UVVis spectroscopy was used to measure the absorbance of the samples over time due to DOX. The PBS at pH 5.5 group released more than the PBS at pH 7.4 group without exposure to the AMF. Meanwhile, at 1 h, 4 h, 8 h, and 12 h, the groups with exposure to the AMF were exposed to the AMF for 1 min. The absorbance of each sample obviously increased aer exposure to the AMF. To summarize, the cumulatively released DOX was 57.6% with the AMF and 32.3% without the AMF in 24 h at pH 7.4. Meanwhile, the AMF was applied to the PBS at pH 5.5 group. The cumulatively released DOX was 78.8% with the AMF and 41.7% without the AMF. Two factors contributed to the pH-response: the solubility of DOX at acidic pH values [43] [44] [45] and the higher solubility of the HPMC/PVA hydrogel at lower pH values.
46 At pH 5.5, the hydrogel starts to be soluble and aids the increased release of DOX. The trend (Fig. 4a) in the PBS at pH 5.5 with AMF group is the same as for the PBS at pH 7.4 with AMF group. HPMC/Fe 3 O 4 /DOX released a signicant amount of DOX aer being exposed to the AMF and at lower pH, while it released little without the AMF and at pH 7.4. The corresponding digital photos of the cumulative release of DOX are shown in Fig. 4b . The increasing color of the tubes shows the accumulation of DOX in different environments. These results conrm that the HPMC/Fe 3 O 4 /DOX hydrogel releases DOX in response to the AMF and the pH. It has been previously reported by many studies that the tumor pH is lower than the pH in normal tissues. Therefore, the pH and magnetic hyperthermia response release behavior triggers the release of the therapeutic anti-cancer drug, DOX, in the acidic tumor microenvironment with little release in neutral environments.
In vitro and vivo biosafety
Human umbilical vein endothelial cells (HUVEC) were cultured to estimate the cell viability via cell count-kit 8 (CCK8). This is a common cell detection method that is oen used to assess cytotoxicity in drug testing. As shown in Fig. 5a , the cell viability was 97.0 AE 1.6% in the control group while the value in the 800 mg mL À1 group was 81.9 AE 3.3%. The cell experiment indicates that the HPMC/Fe 3 O 4 hydrogel has no signicant toxic effects on HUVECs. The serum biochemical indexes of mice were detected at different dosages (0, 1, 2, and 4 mg kg
À1
) and different time points (7 and 14 days). The indicators of liver and renal function, including TP, ALP, AST, ALT, ALB, LDH, BUN, and sCr, reveal no signicant statistic differences (P > 0.05) compared with the control group at 7 days and 14 days aer injection (Fig. 6) . The heart, liver, spleen, lung, and kidney of each mouse were prepared for hematoxylin and eosin staining (H&E staining) to observe their cells (Fig. S2 † and 5b) . No differences between the experimental group and the control group were observed. The experiments in vitro and in vivo demonstrate the high biological safety of the HPMC/Fe 3 O 4 hydrogel.
Ablation efficiency in the excised bovine liver
The ablation range in excised bovine liver was macroscopically measured (Fig. 7a) . Considering the larger ablation range and the smallest dosage of the injected HPMC/Fe 3 O 4 hydrogel, an injection dosage of 60 mL with 10 min of heating time, which caused an ablation radius of 5 mm, was selected for the following in vivo experiments. The macrophotographs of the excised bovine liver were captured (Fig. 7b) and show that the ablation range elongated with longer heating time and with higher injection dosages. The time-ablation distance curves showed increasing ablation distances with increased heating times and increased injection dosages. This can provide guidance for the appropriate heating time in the AMF and appropriate dosage for further in vivo experiments depending on the tumor size to achieve the best ablation effect without damage to normal tissue. As shown in Fig. 7c , the grey values of the magnetic hydrogel detected by ultrasound are different from normal tissue. Aer exposure to the AMF, the cross-sectional area of the HPMC/Fe 3 O 4 /DOX hydrogel decreased. The volumes of the 40, 60, and 80 mL injections of the magnetic hydrogel decreased aer exposure to the AMF for 10 min (Fig. 7d) . These results are not identical to the results obtained in vitro. The change in the volume of the hydrogel depends on the temperature change and the excised bovine liver contains moisture, which affects the increase in temperature. Ultrasound elastography was used to detect the phase transition. In Fig. 7c , the red area is so while the blue area is hard. It is obvious that the HPMC/Fe 3 O 4 /DOX hydrogel is harder than the tissue and aer exposure to AMF the blue region increased in the injection area. It can be inferred that the HPMC/Fe 3 O 4 /DOX hydrogel solidied in the tissue. However, the temperature of the material could not be directly detected because the HPMC/Fe 3 O 4 / DOX hydrogel was injected inside the excised bovine liver. However, the temperature was detected in the previous experiment. Therefore, the combination of ultrasound measurements and elastography may be a potential method to detect the temperature in deep tissue. (Fig. S3a †) . A thermal imager was applied to monitor the temperature changes on the surface of the tumor over time (Fig. 8a, b and S3b †). It has been reported that tumor coagulation necrosis occurs at temperatures above 47 C aer a few minutes of exposure. 28, 47, 48 The temperature on the surface of the center of the tumor above the injected site increased rapidly until it reached 48 AE 1.2 C in 1 min. Aer the hyperthermia expanded to the whole tumor surface, the temperature increased slowly to 68 C during the remaining treatment process. In brief, the temperature of the tumor increased gently during the magnetic hyperthermia treatment process aer the rapid temperature increase in the rst min. This may be due to the release of liquid by the HPMC/Fe 3 O 4 hydrogel to control the heat rising in the tumor tissue and temperature exchanges directly between the injection site and the tumor tissue. To investigate the ablation of the tumor, on the 3 rd day aer treatment, 1 mouse in each group was randomly chosen to be euthanised for tumor H&E staining to investigate the necrosis caused by the treatment. As shown in Fig. 8g , obvious cell necrosis, such as nuclear fragmentation, pyknosis and karyolysis, was observed in the free DOX group, the AMF group and the AMF + DOX group. Normal tumor cells were observed in the free DOX group while no normal tumor cells were observed in the AMF group and the AMF + DOX group, indicating that some tumor cells still survived in the free DOX group. The macrograph (Fig. S3d †) shows a normal tumor in the control group and a smaller tumor in the free DOX group than in the control group, while macroscopic ablation tissue is observed in the AMF and the AMF + DOX groups. The HPMC/Fe 3 O 4 , which had been injected into the tumor, was also found to be gelated into a solid due to the lost water during the AMF heating process. To further demonstrate the therapeutic efficacy, the weight and the tumor volume of each mouse was measured on each day (Fig. 8c, d and S3e †). The tumor volume of the control group increased rapidly, with increasing weight due to the tumor growth. As the tumor grew rapidly, emaciation occurred in the control group and the weight of the mice increased. The tumor volume of mice in the free DOX group was reduced in 7 days together with weight loss, and the spine protruded outward, which suggested that the mice were not healthy due to the effects of the chemotherapy drug DOX. The mice in the free DOX group died successively from the 4 th day aer treatment until 1 mouse remained on the 21 st day, emaciated and in poor spirits. However, the tumor volume in the free DOX group stopped decreasing on the 4 th day, with ongoing weight loss, indicating that unitary chemotherapy did not stop the development of the tumor and its damage the organism. It has been widely reported that DOX causes severe side effects such as acute nausea and vomiting, stomatitis, gastrointestinal disturbances, alopecia baldness and cardiotoxicity. [49] [50] [51] Due to the serious side effects of DOX, only one mouse in the free DOX group survived. As shown in Fig. S3c , † the survival ratio of DOX group signicantly decreased, with no decrease in any other group, which indicates it is DOX that accelerates deaths of the mice. Moreover, the mice in the AMF group and in the AMF with DOX group lost little weight aer the tumor ablation treatment. This illustrates the ability of the HPMC/Fe 3 O 4 hydrogel to diminish the toxicity of DOX, since it has been reported that the character of DOX does not change under the hyperthermia 52 treatment, indicating that the treatment efficiency of DOX is retained during the magnetic hyperthermia treatment. In addition, the AMF enhanced the drug release in the tumor. In this way, the damaging effect of DOX on the normal organism has been limited, while the therapeutic efficacy has been enhanced.
Although no surviving tumor cells were observed in the section from the AMF group, 3 recurrences occurred on the 5 th day, which shows that with longer observation, single magnetic hyperthermia does not inhibit the recurrence of tumors (Fig. 8g and S3e †). On the 21 st day, the mice in the AMF + DOX group recovered to a healthy state and there was no recurrence (Fig. 8g and S3e †), which indicates that chemo-magnetic hyperthermia therapy can treat tumor without recurrence and with lower DOX toxicity. In addition, the measured tumor inhibition ratio of the AMF + DOX group is much higher than that of the other groups, and signicantly higher than the calculated values (additive group) aer 5 days (Fig. 8e) , conrming the efficiency of the chemo-thermal synergistic therapy in vivo. To investigate the health of the mice from each group, the heart, liver, spleen, lung and kidney of mice were obtained for H&E staining. No significant differences can be observed between the normal tissue and the tissue from tumor-bearing mice, indicating that there is no tumor metastasis to the internal organs (Fig. S4 †) . To summarize, free DOX reduced the tumor growth over a period time but damaged the organism and the HPMC/Fe 3 O 4 hydrogel with the AMF could ablate the tumor to some extent but did not prevent recurrence. Combining DOX with the magnetic hyperthermia treatment decreased the tumor recurrence with less damage to the organism.
Conclusion
In this study, an injectable HPMC/Fe 3 O 4 /DOX hydrogel was developed and used for chemo-magnetic hyperthermia tumor therapy. The resulting HPMC/Fe 3 O 4 /DOX hydrogel has pH-sensitive and magnetic response capabilities with high biosafety. As shown by the preliminary results for DOX release in acidic environments and triggered by magnetic hyperthermia, these unique properties provide a signicant step towards tumor therapy applications. More importantly, no tumor recurrences occurred in the chemo-thermal therapy group, while recurrences occurred in the thermal therapy group within 21 days aer the magnetic hyperthermia treatment, which demonstrated the high therapeutic efficacy of chemothermal therapy. This result may be due to enhanced DOX release during magnetic hyperthermia treatment, leading to a synergistic treatment. We believe that this material combined with DOX chemotherapy could improve the therapeutic effects and promote the efficiency, controllability and safety of magnetic hyperthermia treatments, representing a step forward towards clinical applications.
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